Hypothesis

Emodin, a natural anthraquinone, crosses the blood‑brain barrier and improves sleep‑dependent waste clearance by simultaneously inhibiting EGFR signaling in astrocytes and CDK2/cyclin A activity in neurons and glia. This dual action restores perivascular AQP4 polarization, augments glymphatic influx/efflux, and upregulates autophagic flux, thereby increasing the clearance of toxic protein aggregates during sleep.

Mechanistic Rationale

• EGFR inhibition → AQP4 re‑polarization: Reactive astrocyte EGFR signaling drives AQP4 mislocalization, impairing glymphatic flow. Emodin’s suppression of EGFR/MAPK pathways (as shown in peripheral macrophages) should normalize AQP4 anchoring to endfeet, facilitating CSF‑interstitial exchange.
• CDK2 inhibition → autophagy induction: CDK2/cyclin A activity suppresses autophagy initiation. Emodin’s documented CDK2/cyclin A inhibition (in cancer models) is predicted to relieve this brake, boosting LC3‑II conversion and p62 degradation specifically during the sleep‑associated autophagic surge.
• Synergy during sleep: Sleep naturally upregulates both glymphatic influx and autophagy. By targeting the two upstream regulators that hinder these processes, emodin would amplify the brain’s nightly “autopsy,” allowing more efficient verdict on which synapses and proteins persist.

Testable Predictions

1. BBB penetration: Radiolabeled emodin administered intraperitoneally to mice will be detectable in cerebrospinal fluid within 30 min, confirming central exposure.
2. AQP4 localization: In sleep‑deprived mice, emodin treatment will restore the polarized perivascular AQP4 pattern observed in well‑rested controls (immunofluorescence quantification).
3. Glymphatic flux: Intrathecal infusion of fluorescent dextran will show increased CSF‑to‑interstitial tracer clearance rates in emodin‑treated sleep‑deprived mice versus vehicle (whole‑brain imaging).
4. Autophagic flux: Western blots of hippocampal lysates will reveal elevated LC3‑II/I ratios and reduced p62 after emodin administration, specifically during the sleep phase.
5. Cognitive outcome: Mice undergoing chronic sleep fragmentation will exhibit improved performance in novel object recognition and Morris water maze tasks after emodin treatment, correlating with reduced amyloid‑β and tau oligomer loads.
6. Falsifiability: If emodin fails to modify AQP4 polarization, glymphatic tracer kinetics, or autophagic markers despite confirmed brain exposure, the hypothesis is refuted.

Experimental Outline

• Animals: C57BL/6J mice, sleep‑deprived via gentle handling for 6 h before the light phase.
• Groups: Vehicle, emodin low dose (10 mg/kg), emodin high dose (30 mg/kg), plus a positive control (known glymphatic enhancer, e.g., intrathecal c‑AMP analog).
• Readouts: BBB penetration (LC‑MS/MS), AQP4 immunofluorescence, intrathecal tracer clearance (IVIS imaging), autophagic markers (Western blot, immunohistochemistry), ELISA for Aβ/tau, behavioral assays.
• Statistics: Two‑way ANOVA (treatment × sleep condition) with post‑hoc Tukey; significance set at p < 0.05.

If validated, this work would reposition emodin from a peripheral anti‑inflammatory agent to a modulator of the brain’s intrinsic nocturnal quality‑control system, offering a mechanistic bridge between sleep hygiene and neurodegenerative disease prevention.